SEP 29, 2019 9:38 AM PDT

Researchers Can Now Reverse Skin Cancer

WRITTEN BY: Annie Lennon

Ten years ago, just 5% of people with advanced melanoma (skin cancer) lived more than five years after being diagnosed. Now however, researchers from the Institute of Cancer Research and the Royal Marsden hospital in London have found a way to increase the chances of living beyond five years with the condition to 52% (Boseley: 2019). But how? 

In a stage 3 clinical trial, the researchers tested a combination of two immunotherapy drugs: ipilimumab and nivolumab, to understand how they influence cancer growth. In doing so, they randomized 945 patients with advanced melanoma into three groups: 314 receiving a double dosage of nivolumab plus ipilimumab; 316 receiving nivolumab and a placebo; and 315 receiving ipilimumab and a placebo (Larkin: 2019). 

Comparing the results of each group until the disease either progressed or side-effects became unbearable, they found that the group taking a combination of the two drugs had the best prognosis. Their survival rate after five years was 52%, with 74% of those patients being able to live treatment-free after five years of initial treatment. Meanwhile, the survival rate for nivolumab alone was 44%, and that for ipilimumab: 26% (ibid.). 

Professor James Larkin, involved in the study, said: “By giving these drugs together you are effectively taking two brakes off the immune system rather than one so that the immune system is able to recognise tumours it wasn't previously recognising and react to that and destroy them (The Institute of Cancer Research: 2019).”

Moreover, the researchers also noticed that even for patients who stopped treatment due to unbearable side effects such as fatigue, skin rashes and diarrhea, their outcomes were just as good as for those who had continued to take the drugs over longer periods of time. This is because immune systems can be re-educated even with just a short duration of treatment, contrasting other treatments such as chemotherapy, which require a full course to be effective (ibid.). 

According to Pamela Smith, one of the participants in the trial: “I’d been having treatment every two weeks for about four months when I developed diarrhoea that was so bad I had to come off treatment. Amazingly, the first scan and every scan since has shown that in that relatively short time, it worked. My tumour shrank to less than half its original size and it hasn’t changed in five years (Boseley: 2019).”

 

Sources

 

Boseley, Sarah: The Guardian 

Larkin, James: The New England Journal of Medicine

The Institute of Cancer Research 

 

About the Author
  • Science writer with a keen interest in behavioral biology, consciousness medicine and technology. Her current focus is how the interplay of these fields can create meaningful interactions, products and environments.
You May Also Like
MAR 04, 2021
Drug Discovery & Development
How Placebo Drugs for Pain Work in the Brain
MAR 04, 2021
How Placebo Drugs for Pain Work in the Brain
Researchers from Dartmouth College have found that pain relief drugs that work via the placebo effect reduce pain-relate ...
MAR 06, 2021
Genetics & Genomics
Green Tea Extract Can Affect Facial Development in Kids With Down Syndrome
MAR 06, 2021
Green Tea Extract Can Affect Facial Development in Kids With Down Syndrome
Individuals with Down syndrome often have certain facial features. New research has suggested that green tea supplements ...
APR 13, 2021
Immunology
The "Unexpected" Reason Why COVID Antivirals Don't Work
APR 13, 2021
The "Unexpected" Reason Why COVID Antivirals Don't Work
Purdue University researchers have made a breakthrough finding that could explain why the disease is so hard to manage t ...
MAY 04, 2021
Health & Medicine
Micro-dosing Inhaler Breakthrough for Medical Cannabis
MAY 04, 2021
Micro-dosing Inhaler Breakthrough for Medical Cannabis
In a leap that will eliminate the risks of vaping or smoking, Canada has just approved an Israeli-made inhaler that is a ...
JUN 17, 2021
Drug Discovery & Development
New COVID Drug Reduces Deaths in Patients with no Antibodies
JUN 17, 2021
New COVID Drug Reduces Deaths in Patients with no Antibodies
US drugmaker, Regeneron, in a partnership with Oxford University, has found that its new drug is capable of reducing COV ...
JUN 17, 2021
Drug Discovery & Development
FDA Approval of First New Alzheimer's Drug in Two Decades Sparks Controversy
JUN 17, 2021
FDA Approval of First New Alzheimer's Drug in Two Decades Sparks Controversy
The FDA recently approved a new drug known as Adulhelm, or aducanumab, to treat Alzheimer’s disease. The first new ...
Loading Comments...